Rachel Lynn Salzman
Oprichter bij SwanBio Therapeutics, Inc.
Oorsprong van het eerstegraads netwerk van Rachel Lynn Salzman
| Entiteit | Type entiteit | Industrie | |
|---|---|---|---|
SwanBio Therapeutics, Inc.
 SwanBio Therapeutics, Inc. BiotechnologyHealth Technology SwanBio Therapeutics, Inc. operates as a gene therapy firm. The company was founded by Tom Anderson, Rachel Salzman, Karen Kozarsky and Florian S. Eichler and is headquartered in Bala Cynwyd, PA.
8
| Private Company | Biotechnology | 8 |
Swanbio Therapeutics Ltd.
 Swanbio Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Swanbio Therapeutics Ltd. engages in the research and experimental development of biotechnology. The company was founded on September 1, 2017 and is headquartered in London, the United Kingdom.
2
| Holding Company | Miscellaneous Commercial Services | 2 |
Grafiek van bedrijven verbonden in de tweede graad
Connectie in verschillende bedrijven
Bedrijven verbonden met Rachel Lynn Salzman via zijn persoonlijke netwerk
| Onderneming | Sector | Gelieerde personen | Hoofdpost |
|---|---|---|---|
| AMGEN INC. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
| BRISTOL-MYERS SQUIBB COMPANY | Pharmaceuticals: Major | Private Equity Investor | |
| Washington University in St. Louis | College/University | Undergraduate Degree | |
| MERCK KGAA | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
| ACADIA PHARMACEUTICALS INC. | Pharmaceuticals: Major | Corporate Officer/Principal | |
| ATYR PHARMA, INC. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
Regulatory Affairs Professionals Society
 Regulatory Affairs Professionals Society Miscellaneous Commercial ServicesCommercial Services Regulatory Affairs Professionals Society is a non-profit organization that offers healthcare products. The non-profit company is based in Rockville, MD. | Miscellaneous Commercial Services | Chairman | |
| REGENXBIO INC. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
| SYNCONA LIMITED | Investment Trusts/Mutual Funds | Corporate Officer/Principal | |
| NOVARTIS AG | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
| University of Pennsylvania | College/University | Corporate Officer/Principal | |
| University of Oxford | College/University | Graduate Degree | |
| University of Cambridge | College/University | Doctorate Degree Doctorate Degree | |
| ALNYLAM PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director of Finance/CFO | |
| Amherst College | College/University | Undergraduate Degree | |
| Massachusetts Institute of Technology | College/University | Doctorate Degree | |
| Brandeis University | College/University | Undergraduate Degree | |
| Colgate University | College/University | Undergraduate Degree | |
| University of California San Diego | College/University | Corporate Officer/Principal | |
| University of Vermont | College/University | Corporate Officer/Principal | |
| APPLIED GENETIC TECHNOLOGIES CORPORATION | Pharmaceuticals: Generic | Director/Board Member | |
EMD Serono, Inc.
 EMD Serono, Inc. Pharmaceuticals: MajorHealth Technology EMD Serono, Inc. operates as a biopharmaceutical firm. The firm develops recombinant prescription medicines. Its therapies include neurology and immunology, metabolic endocrinology, fertility, and oncology. The company was founded in 1971 and is headquartered in Rockland, MA. | Pharmaceuticals: Major | Corporate Officer/Principal | |
| Winchester College | College/University | Undergraduate Degree | |
| King's College London | College/University | Undergraduate Degree | |
Novartis Institute for Functional Genomics, Inc.
 Novartis Institute for Functional Genomics, Inc. Miscellaneous Commercial ServicesCommercial Services Novartis Institute For Functional Genomics, Inc. serves as a bridge between basic science and preclinical drug discovery for Novartis’ global research organization. Its focus areas include oncology, autoimmunity, cardiovascular disease, diabetes, musculoskeletal disorders, and infectious disease. The company was founded in 1999 and is headquartered in San Diego, CA. | Miscellaneous Commercial Services | Director/Board Member | |
Novartis Pharma AG
 Novartis Pharma AG Pharmaceuticals: MajorHealth Technology Novartis Pharma AG engages in the research in as well as the production and distribution of pharmaceutical, chemical, medical, and biotechnological products. It also provides related services. The company was founded on October 25, 1989 and is headquartered in Basel, Switzerland. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
GlaxoSmithKline LLC
 GlaxoSmithKline LLC Pharmaceuticals: MajorHealth Technology GlaxoSmithKline LLC engages in discovering, developing, and delivering medicines, vaccines, and other healthcare products. It offers prescription medicines that treat various diseases, including cancer, HIV/AIDS, depression, diabetes, high blood pressure, herpes, asthma, migraine, and heart diseases, as well as stomach and skin problems, infections, and flu. It also provides vaccines for children and adults; and over-the-counter products. The company was founded in 1929 and is headquartered in Philadelphia, PA. | Pharmaceuticals: Major | Corporate Officer/Principal | |
| BLUEPRINT MEDICINES CORPORATION | Biotechnology | Director/Board Member | |
Lumos Pharma Sub, Inc.
 Lumos Pharma Sub, Inc. Medical/Nursing ServicesHealth Services Lumos Pharma Sub, Inc. develops and commercializes a novel treatment for the rare disease creatine transporter deficiency. It focuses on bringing novel therapies to patients afflicted with unmet medical needs in severe, rare, and genetic diseases. The firm's technology LUM-001 is a repurposed small molecule that is a kinetically similar analog of creatine and has shown promising therapeutic potential for the treatment of creatine transporter deficiency. Lumos Pharma was founded by Richard J. Hawkins in 2010 and is headquartered in Austin, TX. | Medical/Nursing Services | Chief Tech/Sci/R&D Officer | |
Syncona Partners LLP
 Syncona Partners LLP Investment ManagersFinance Syncona Partners LLP (Syncona Partners) is a venture capital subsidiary of Syncona Investment Management Ltd. founded in 2012 by Martin Murphy. The firm is headquartered in London, United Kingdom. | Investment Managers | Chief Executive Officer Private Equity Investor Private Equity Investor Private Equity Investor | |
| The Wharton School of the University of Pennsylvania | College/University | Masters Business Admin | |
| Sackler School of Medicine | College/University | Doctorate Degree | |
| University of Louisville School of Medicine | College/University | Doctorate Degree | |
NightstaRx Ltd.
 NightstaRx Ltd. Medical/Nursing ServicesHealth Services NightstaRx Ltd. develops and commercializes therapies for retinal dystrophies. It offers retinal gene therapy that provides one-time cure for choroideremia (a rare inherited cause of blindness) and other retinal dystrophies. The company was founded by Robert MacLaren, Miguel Seabra, and Matthew During in January 2014 and is headquartered in London, the United Kingdom. | Medical/Nursing Services | Director/Board Member | |
Vividion Therapeutics, Inc.
 Vividion Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Vividion Therapeutics, Inc. operates as a biotechnology company. The company focuses on developing innovative therapeutics that treat major unmet clinical needs using the first platform for proteome wide drug and target discovery. It's proprietary chemoproteomic platform technology addresses the key limitations of conventional screening techniques and allows the discovery of previously unknown, or cryptic, functional pockets on the surface of proteins and identification of small molecules that selectively bind to those targets. The company was founded by Benjamin F. Cravatt, Phil S. Baran, Jin-Quan Yu and John K. Clarke on December 24, 2013 and is headquartered in San Diego, CA. | Miscellaneous Commercial Services | Director of Finance/CFO | |
Anaveon AG
 Anaveon AG BiotechnologyHealth Technology Anaveon AG engages in the development of immune therapies against cancer. Its compounds promote effector T-cell functions to enhance a patient?s immune system to respond to tumors. The company was founded on December 11, 2017 by Onur Boyman and Andreas Katopodis and is headquartered in Bottmingen, Switzerland. | Biotechnology | Director/Board Member | |
AxoSim, Inc.
 AxoSim, Inc. Packaged SoftwareTechnology Services Axosim, Inc. operates as a biotechnology company that develops nerve-on-a-chip platform. The company was founded by Lowry Curley and Michael Moore and is headquartered in New Orleans, LA. | Packaged Software | Chairman | |
Gyroscope Therapeutics Ltd.
 Gyroscope Therapeutics Ltd. BiotechnologyHealth Technology Gyroscope Therapeutics Ltd. operates as an ophthalmology firm. It develops a cutting edge, genetically-defined therapies for the treatment of eye diseases linked to an unbalanced complement system. The company was founded on April 18, 2016 and is headquartered in Stevenage, the United Kingdom. | Biotechnology | Chairman | |
| FREELINE THERAPEUTICS HOLDINGS PLC | Biotechnology | Chairman | |
| BRIGHT MINDS BIOSCIENCES INC. | Biotechnology | Director/Board Member | |
Purespring Therapeutics Ltd.
 Purespring Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Purespring Therapeutics Ltd. provides biotechnological research and experimental development services. The company was founded on April 1, 2020 and is headquartered in London, the United Kingdom. | Miscellaneous Commercial Services | Chairman | |
| CHEMOMAB THERAPEUTICS LTD. | Biotechnology | Chief Tech/Sci/R&D Officer | |
| GYROSCOPE THERAPEUTICS HOLDINGS PLC | Biotechnology | Chairman | |
| Forcefield Therapeutics Ltd. | Chairman Chief Executive Officer | ||
| AYTU BIOPHARMA, INC. | Pharmaceuticals: Major | Chief Operating Officer |
Statistieken
Internationaal
| Verenigde Staten | 31 |
| Verenigd Koninkrijk | 13 |
| Zwitserland | 4 |
| Israël | 3 |
| Duitsland | 2 |
Sectoraal
| Health Technology | 23 |
| Consumer Services | 15 |
| Commercial Services | 5 |
| Finance | 4 |
| Health Services | 3 |
Operationeel
| Director/Board Member | 39 |
| Corporate Officer/Principal | 18 |
| Independent Dir/Board Member | 13 |
| Chairman | 12 |
| Chief Tech/Sci/R&D Officer | 11 |
Sterkste connecties
| Insiders | |
|---|---|
| Alison Lawton | 24 |
| Chris Hollowood | 19 |
| Patricia Allen | 14 |
| David Weiner | 14 |
| John Tsai | 10 |
| Karen F. Kozarsky | 6 |
| Alex Hamilton | 6 |
| Danny Bar-Zohar | 5 |
| Christopher Brooke | 5 |
| Julius John Sheldon Knowles | 1 |
- Beurs
- Insiders
- Rachel Lynn Salzman
- Bedrijfsconnecties